148 related articles for article (PubMed ID: 22408187)
1. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
Molife LR; Alam S; Olmos D; Puglisi M; Shah K; Fehrmann R; Trani L; Tjokrowidjaja A; de Bono JS; Banerji U; Kaye SB
Ann Oncol; 2012 Aug; 23(8):1968-1973. PubMed ID: 22408187
[TBL] [Abstract][Full Text] [Related]
2. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience.
Wheler JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Moulder S; Stephen B; Wen S; Kurzrock R
Ann Oncol; 2012 Aug; 23(8):1963-1967. PubMed ID: 22377564
[TBL] [Abstract][Full Text] [Related]
3. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
4. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
[TBL] [Abstract][Full Text] [Related]
5. Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.
Altzerinakou MA; Collette L; Paoletti X
J Natl Cancer Inst; 2019 Nov; 111(11):1179-1185. PubMed ID: 30838405
[TBL] [Abstract][Full Text] [Related]
6. Determinants of the recommended phase 2 dose of molecular targeted agents.
Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
[TBL] [Abstract][Full Text] [Related]
7. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
Colin P; Micallef S; Delattre M; Mancini P; Parent E
Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
[TBL] [Abstract][Full Text] [Related]
8. Revisiting Risk and Benefit in Early Oncology Trials in the Era of Precision Medicine: A Systematic Review and Meta-Analysis of Phase I Trials of Targeted Single-Agent Anticancer Therapies.
Mackley MP; Fernandez NR; Fletcher B; Woolcott CG; Fernandez CV
JCO Precis Oncol; 2021 Nov; 5():17-26. PubMed ID: 34994588
[TBL] [Abstract][Full Text] [Related]
9. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?
Postel-Vinay S; Gomez-Roca C; Molife LR; Anghan B; Levy A; Judson I; De Bono J; Soria JC; Kaye S; Paoletti X
J Clin Oncol; 2011 May; 29(13):1728-35. PubMed ID: 21444876
[TBL] [Abstract][Full Text] [Related]
10. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.
Hirakawa A; Yonemori K; Kinoshita F; Kobayashi Y; Okuma HS; Kawachi A; Tamura K; Fujiwara Y; Rubinstein L; Harris PJ; Takebe N
Cancer Sci; 2018 Jan; 109(1):207-214. PubMed ID: 29114963
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
[TBL] [Abstract][Full Text] [Related]
12. Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.
Basu B; Vitfell-Pedersen J; Moreno Garcia V; Puglisi M; Tjokrowidjaja A; Shah K; Malvankar S; Anghan B; de Bono JS; Kaye SB; Molife LR; Banerji U
Oncology; 2012; 83(4):177-82. PubMed ID: 22889980
[TBL] [Abstract][Full Text] [Related]
13. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.
Paoletti X; Geoerger B; Doz F; Baruchel A; Lokiec F; Le Tourneau C
Eur J Cancer; 2013 Jul; 49(10):2392-402. PubMed ID: 23540589
[TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
[TBL] [Abstract][Full Text] [Related]
17. A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.
Dorris K; Liu C; Li D; Hummel TR; Wang X; Perentesis J; Kim MO; Fouladi M
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27654490
[TBL] [Abstract][Full Text] [Related]
18. Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
Roda D; Jimenez B; Banerji U
Clin Cancer Res; 2016 May; 22(9):2127-32. PubMed ID: 26581244
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
[TBL] [Abstract][Full Text] [Related]
20. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Chan KK; Glenny AM; Weldon JC; Furness S; Worthington HV; Wakeford H
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010341. PubMed ID: 26625332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
